Hemophilia
Biogen To Spin Off Hemophilia Drug Business Into A Public Company
Biogen Inc said on Tuesday it would spin off its hemophilia drug business as a publicly traded company in a tax-free transaction, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases. 
Improvements In Hemophilia Treatment Do Not Extend To Uninsured Patients
Despite positive medical progress, many men living with hemophilia face treatment disparities and frequent bleeding. 
FDA Approves Baxalta's Drug For Rare Bleeding Disorder
Baxalta Inc's drug, Adynovate, has been approved to control and reduce the frequency of bleeding episodes in patients with Hemophilia A, the agency said in a statement on Friday. 
New Virus Similar To Hepatitis C Can Be Transmitted Through Blood Transfusions; It's Probably Not Harmful
A new virus has been found to be transmitted through blood transfusions, but it doesn't seem dangerous. Pfizer receives FDA approval for prefilled dual-chamber syringe for use in the treatment of Hemophilia A
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress
Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress.
